Frontiers in Endocrinology,
Год журнала:
2023,
Номер
14
Опубликована: Июль 3, 2023
Characterized
by
a
complex
pathophysiology
that
includes
the
intraneuronal
formation
of
neurofibrillary
tangles
and
extracellular
deposition
β-amyloid
plaques,
Alzheimer’s
disease
(AD)
is
terminal
neurodegenerative
causes
dementia
in
older
adults.
Oxidative
stress
brain
considered
as
one
contributing
factors
to
pathogenesis
AD,
thus,
antioxidants
have
attracted
much
interest
potential
therapeutic
agents
against
disorder.
Natural
are
typically
characterized
low
acute
chronic
toxicity,
which
facilitates
their
application.
One
important
molecular
target
for
beneficial
effects
natural
nuclear
factor
erythroid-derived
2-related
2
(NFE2L2/NRF2).
NRF2
key
transcription
orchestrates
cellular
antioxidant
response
through
regulating
expression
oxidative
stress-related
genes
harboring
element
(ARE)
promoters.
Indeed,
case
excessive
damage,
migrates
nucleus
binds
ARE,
activating
protector
genes.
There
increasing
evidence
implicated
AD
pathology
dysfunction
altered
localization,
renders
it
AD.
Thus,
this
review
summarizes
most
recent
(2018-2023)
advances
on
NRF2-modulating
activity
observed
vitro
animal
models.
This
information
will
help
elucidate
mechanisms
governing
such
phytochemicals
highlight
common
diseases,
Frontiers in Pharmacology,
Год журнала:
2023,
Номер
14
Опубликована: Окт. 18, 2023
Increased
production
and
buildup
of
reactive
oxygen
species
(ROS)
can
lead
to
various
health
issues,
including
metabolic
problems,
cancers,
neurological
conditions.
Our
bodies
counteract
ROS
with
biological
antioxidants
such
as
SOD,
CAT,
GPx,
which
help
prevent
cellular
damage.
However,
if
there
is
an
imbalance
between
these
antioxidants,
it
result
in
oxidative
stress.
This
cause
genetic
epigenetic
changes
at
the
molecular
level.
review
delves
into
how
plays
a
role
disorders
caused
by
We
also
look
animal
models
used
for
researching
pathways.
study
offers
insights
mechanism,
pathology,
changes,
assist
drug
development
disease
understanding.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(3), С. 1869 - 1869
Опубликована: Янв. 18, 2023
Aging
is
the
most
prominent
risk
factor
for
late-onset
Alzheimer’s
disease.
associates
with
a
chronic
inflammatory
state
both
in
periphery
and
central
nervous
system,
evidence
thereof
mechanisms
leading
to
neuroinflammation
being
discussed.
Nonetheless,
significantly
enhanced
by
accumulation
of
amyloid
beta
accelerates
progression
disease
through
various
pathways
discussed
present
review.
Decades
clinical
trials
targeting
2
abnormal
proteins
disease,
tau,
led
many
failures.
As
such,
via
different
strategies
could
prove
valuable
therapeutic
strategy,
although
much
research
still
needed
identify
appropriate
time
window.
Active
focusing
on
identifying
early
biomarkers
help
translating
these
novel
from
bench
bedside.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(5), С. 2698 - 2698
Опубликована: Фев. 26, 2024
Oxidative
stress
(OS)
and
inflammation
are
two
important
well-studied
pathological
hallmarks
of
neurodegenerative
diseases
(NDDs).
Due
to
elevated
oxygen
consumption,
the
high
presence
easily
oxidizable
polyunsaturated
fatty
acids
weak
antioxidant
defenses,
brain
is
particularly
vulnerable
oxidative
injury.
Uncertainty
exists
over
whether
these
deficits
contribute
development
NDDs
or
solely
a
consequence
neuronal
degeneration.
Furthermore,
linked,
it
known
that
OS
can
affect
inflammatory
response.
In
this
review,
we
will
overview
last
findings
about
pathways
in
principal
NDDs.
Moreover,
focus
more
depth
on
amyotrophic
lateral
sclerosis
(ALS)
understand
how
anti-inflammatory
antioxidants
drugs
have
been
used
for
treatment
still
incurable
motor
neuron
(MN)
disease.
Finally,
analyze
past
actual
clinical
trials
future
perspectives
study
mechanisms.
Acta Pharmaceutica Sinica B,
Год журнала:
2024,
Номер
15(1), С. 15 - 34
Опубликована: Окт. 16, 2024
Neuroprotection
is
a
proactive
approach
to
safeguarding
the
nervous
system,
including
brain,
spinal
cord,
and
peripheral
nerves,
by
preventing
or
limiting
damage
nerve
cells
other
components.
It
primarily
defends
central
system
against
injury
from
acute
progressive
neurodegenerative
disorders.
Oxidative
stress,
an
imbalance
between
body's
natural
defense
mechanisms
generation
of
reactive
oxygen
species,
crucial
in
developing
neurological
Due
its
high
metabolic
rate
consumption,
brain
particularly
vulnerable
oxidative
stress.
Excessive
ROS
damages
essential
biomolecules,
leading
cellular
malfunction
neurodegeneration.
Several
disorders,
Alzheimer's,
Parkinson's,
Amyotrophic
lateral
sclerosis,
multiple
ischemic
stroke,
are
associated
with
Understanding
impact
stress
these
conditions
for
new
treatment
methods.
Researchers
exploring
using
antioxidants
molecules
mitigate
aiming
prevent
slow
down
progression
diseases.
By
understanding
intricate
interplay
scientists
hope
pave
way
innovative
therapeutic
preventive
approaches,
ultimately
improving
individuals'
living
standards.
International Journal of Molecular Sciences,
Год журнала:
2022,
Номер
23(21), С. 13630 - 13630
Опубликована: Ноя. 7, 2022
Alzheimer’s
disease
(AD)
is
a
frequent
and
disabling
neurodegenerative
disorder,
in
which
astrocytes
participate
several
pathophysiological
processes
including
neuroinflammation,
excitotoxicity,
oxidative
stress
lipid
metabolism
(along
with
critical
role
apolipoprotein
E
function).
Current
evidence
shows
that
have
both
neuroprotective
neurotoxic
effects
depending
on
the
stage
microenvironmental
factors.
Furthermore,
appear
to
be
affected
by
presence
of
amyloid-beta
(Aβ),
alterations
calcium
levels,
gliotransmission
proinflammatory
activity
via
RAGE-NF-κB
pathway.
In
addition,
play
an
important
tau
clearance
Aβ
through
glymphatic
system.
this
review,
we
will
discuss
novel
pharmacological
non-pharmacological
treatments
focused
as
therapeutic
targets
for
AD.
These
interventions
include
anti-inflammatory/antioxidant
systems,
glutamate
activity,
metabolism,
neurovascular
coupling
system,
dysregulation,
release
peptides
affects
glial
neuronal
function.
According
AD
stage,
these
therapies
may
benefit
either
preventing
or
delaying
progression
disease.
Antioxidants,
Год журнала:
2022,
Номер
11(11), С. 2167 - 2167
Опубликована: Окт. 31, 2022
Alzheimer’s
disease
(AD),
the
most
common
form
of
dementia,
has
increasing
incidence,
mortality
rates,
and
poses
a
huge
burden
on
healthcare.
None
currently
approved
drugs
for
treatment
AD
influence
progression.
Many
clinical
trials
aiming
at
inhibiting
amyloid
plaque
formation,
beta
clearance,
or
neurofibrillary
tangle
pathology
yielded
inconclusive
results
failed.
Meanwhile,
research
identified
many
interlinked
vicious
cascades
implicating
oxidative
stress,
mitochondrial
dysfunction,
chronic
neuroinflammation,
pointed
to
novel
therapeutic
targets
such
as
improving
bioenergetics
quality
control,
diminishing
modulating
neuroinflammatory
pathways.
molecules
tested
in
vitro
animal
models
have
proven
efficient,
but
their
translation
into
clinic
needs
further
regarding
appropriate
doses,
delivery
routes,
possible
side
effects.
Cell-based
therapies
extracellular
vesicle-mediated
messenger
RNAs
microRNAs
seem
also
promising
strategies
allowing
target
specific
signaling
pathways,
need
harvesting
culture
methods
well
control
tumorigenic
The
rapidly
developing
area
nanotechnology
could
improve
drug
be
used
early
diagnosis.
Molecular Neurobiology,
Год журнала:
2023,
Номер
60(8), С. 4169 - 4183
Опубликована: Апрель 12, 2023
Telomeres,
also
known
as
the
"protective
caps"
of
our
chromosomes,
shorten
with
each
cell
cycle
due
to
end
replication
problem.
This
process,
termed
telomere
attrition,
is
associated
many
age-related
disorders,
such
Alzheimer's
disease
(AD).
Despite
numerous
studies
conducted
in
this
field,
role
attrition
onset
remains
unclear.
To
investigate
causal
relationship
between
short
telomeres
and
AD,
review
aims
highlight
primary
factors
that
regulate
length
maintain
its
integrity,
an
additional
outlook
on
oxidative
stress,
which
commonly
aging
molecular
damage.
Although
some
findings
thus
far
might
be
contradictory,
likely
plays
a
crucial
progression
AD
close
association
stress.
The
currently
available
treatments
for
are
only
symptomatic
without
affecting
disease.
components
biology
discussed
paper
have
previously
been
studied
alternative
treatment
option
several
diseases
exhibited
promising
vitro
vivo
results.
Hence,
should
provide
basis
future
research
develop
potential
therapeutic
strategy
AD.
(Created
BioRender.com).